

# Jnwn Barker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6716667/publications.pdf>

Version: 2024-02-01

227  
papers

34,708  
citations

10389

72  
h-index

4342

173  
g-index

241  
all docs

241  
docs citations

241  
times ranked

49011  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-stage, adaptive placebo-controlled trial (APRICOT)*. <i>British Journal of Dermatology</i> , 2022, 186, 245-256.	1.5	22
2	Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. <i>Lancet Rheumatology</i> , The, 2022, 4, e42-e52.	3.9	66
3	Differences in Clinical Features and Comorbid Burden between HLA-C*06:02 Carrier Groups in >9,000 People with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1617-1628.e10.	0.7	11
4	Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. <i>British Journal of Dermatology</i> , 2022, 187, 254-256.	1.5	11
5	Genome-wide association meta-analysis identifies 29 new acne susceptibility loci. <i>Nature Communications</i> , 2022, 13, 702.	12.8	23
6	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. <i>Efficacy and Mechanism Evaluation</i> , 2022, 9, 1-106.	0.7	1
7	INFLUENCE OF FLG LOSS-OF-FUNCTION MUTATIONS IN HOST-MICROBE INTERACTIONS DURING ATOPIC SKIN INFLAMMATION. <i>Journal of Dermatological Science</i> , 2022, , .	1.9	0
8	Biomarkers of disease progression in people with psoriasis: a scoping review. <i>British Journal of Dermatology</i> , 2022, 187, 481-493.	1.5	22
9	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. <i>Arthritis and Rheumatology</i> , 2022, 74, 1535-1543.	5.6	15
10	Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 882-893.	2.9	21
11	Biomarkers of systemic treatment response in people with psoriasis: a scoping review. <i>British Journal of Dermatology</i> , 2022, 187, 494-506.	1.5	14
12	Microbial and transcriptional differences elucidate atopic dermatitis heterogeneity across skin sites. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1173-1187.	5.7	16
13	Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	2.9	136
14	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey*. <i>British Journal of Dermatology</i> , 2021, 185, 80-90.	1.5	26
15	Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e498-e501.	2.4	2
16	Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis Severity. <i>JAMA Dermatology</i> , 2021, 157, 413.	4.1	18
17	Psoriasis: a brief overview. <i>Clinical Medicine</i> , 2021, 21, 170-173.	1.9	87
18	Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e496-e498.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Defining trajectories of response in patients with psoriasis treated with biologic therapies. <i>British Journal of Dermatology</i> , 2021, 185, 825-835.	1.5	4
20	CYP1A1 Enzymatic Activity Influences Skin Inflammation Via Regulation of the AHR Pathway. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1553-1563.e3.	0.7	34
21	Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e636-e640.	2.4	18
22	Enhanced NF- $\kappa$ B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. <i>Nature Communications</i> , 2021, 12, 4741.	12.8	23
23	The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e627-e637.	3.9	132
24	Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis. <i>Clinical Drug Investigation</i> , 2021, 41, 1011-1020.	2.2	10
25	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
26	Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. <i>Scientific Reports</i> , 2021, 11, 23335.	3.3	10
27	Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. <i>Journal of Dermatological Treatment</i> , 2020, 31, 794-800.	2.2	26
28	IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 816-826.e3.	0.7	64
29	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 117-122.	1.2	120
30	Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Therapeutics Update). <i>Journal of Investigative Dermatology</i> , 2020, 140, 1516-1523.e3.	0.7	50
31	T-cell phenotyping uncovers systemic features of atopic dermatitis and psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1021-1025.e15.	2.9	13
32	Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. <i>American Journal of Human Genetics</i> , 2020, 107, 539-543.	6.2	44
33	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. <i>JAMA Dermatology</i> , 2020, 156, 1216.	4.1	18
34	ESDR 2010-2020: Journey toward Translational and Systems Dermatology. <i>Journal of Investigative Dermatology</i> , 2020, 140, S167-S170.	0.7	0
35	Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. <i>Clinical and Translational Science</i> , 2020, 13, 400-409.	3.1	9
36	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2129-2137.	0.7	6

#	ARTICLE	IF	CITATIONS
37	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. <i>Trials</i> , 2020, 21, 158.	1.6	7
38	Psoriasis and Genetics. <i>Acta Dermato-Venereologica</i> , 2020, 100, 55-65.	1.3	64
39	Clinical and genetic differences between pustular psoriasis subtypes. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1021-1026.	2.9	165
40	Morphologic Switch From Psoriasiform to Eczematous Dermatitis After Anti-IL-17 Therapy. <i>JAMA Dermatology</i> , 2019, 155, 1082.	4.1	10
41	Microbe-host interplay in atopic dermatitis and psoriasis. <i>Nature Communications</i> , 2019, 10, 4703.	12.8	217
42	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1235.	4.1	30
43	Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk. <i>Human Molecular Genetics</i> , 2019, 28, 3498-3513.	2.9	65
44	Prevalence of Advanced Liver Fibrosis in Patients With Severe Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1028.	4.1	17
45	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 1265-1271.	1.5	15
46	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 810-811.	2.9	2
47	Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02. <i>Nature Communications</i> , 2019, 10, 1150.	12.8	82
48	What does acne genetics teach us about disease pathogenesis?. <i>British Journal of Dermatology</i> , 2019, 181, 665-676.	1.5	32
49	Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic. <i>British Journal of Dermatology</i> , 2019, 181, 946-953.	1.5	56
50	Pustular Forms of Psoriasis Related to Autoinflammation. , 2019, , 471-484.		2
51	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2120-2130.	2.9	128
52	Clinical outcomes in patients on secukinumab (Cosentyx <sup>®</sup> ) within a specialist psoriasis clinic: a single centre, retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e89-e91.	2.4	3
53	Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 115-123.	0.7	60
54	Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom. <i>Cogent Medicine</i> , 2018, 5, 1495593.	0.7	4

#	ARTICLE	IF	CITATIONS
55	Genome-wide meta-analysis implicates mediators of hair follicle development and morphogenesis in risk for severe acne. <i>Nature Communications</i> , 2018, 9, 5075.	12.8	48
56	Genetic correlations among psychiatric and immune-related phenotypes based on genome-wide association data. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 641-657.	1.7	158
57	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. <i>Trials</i> , 2018, 19, 465.	1.6	15
58	The Psoriasis Risk Allele <i>HLA-C*06:02</i> Shows Evidence of Association with Chronic or Recurrent Streptococcal Tonsillitis. <i>Infection and Immunity</i> , 2018, 86, .	2.2	17
59	Juvenile generalized pustular psoriasis is a chronic recalcitrant disease: an analysis of 27 patients seen in a tertiary hospital in Johor, Malaysia. <i>International Journal of Dermatology</i> , 2017, 56, 392-399.	1.0	22
60	European consensus statement on phenotypes of pustular psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1792-1799.	2.4	269
61	Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. <i>Nature Communications</i> , 2017, 8, 15382.	12.8	251
62	miR-146b Probably Assists miRNA-146a in the Suppression of Keratinocyte Proliferation and Inflammatory Responses in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1945-1954.	0.7	68
63	Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. <i>British Journal of Dermatology</i> , 2017, 177, 637-644.	1.5	8
64	An analysis of IL-36 signature genes and individuals with <i>IL1RL2</i> knockout mutations validates IL-36 as a psoriasis therapeutic target. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	124
65	European Society for Dermatological Research (ESDR): Shifting Scope and Expanding Boundaries, Promoting Cutaneous Biology Research across Europe and beyond. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1817-1819.	0.7	2
66	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1774-1779.	0.9	51
67	Tumour necrosis factor antagonist-induced lupus: a Critically Appraised Topic. <i>British Journal of Dermatology</i> , 2017, 177, 1519-1526.	1.5	6
68	Acne and Telomere Length: A New Spectrum between Senescence and Apoptosis Pathways. <i>Journal of Investigative Dermatology</i> , 2017, 137, 513-515.	0.7	6
69	Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. <i>British Journal of Dermatology</i> , 2017, 176, 1028-1034.	1.5	88
70	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. <i>Human Molecular Genetics</i> , 2017, 26, 4301-4313.	2.9	41
71	THU0004...Cross phenotype association mapping of the mhc identifies genetic variants that differentiate psoriatic arthritis from psoriasis. , 2017, , .		0
72	Phenome-wide association study using research participants' self-reported data provides insight into the Th17 and IL-17 pathway. <i>PLoS ONE</i> , 2017, 12, e0186405.	2.5	16

#	ARTICLE	IF	CITATIONS
73	AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2251-2259.	0.7	128
74	Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise. <i>British Journal of Dermatology</i> , 2016, 174, 212-215.	1.5	6
75	Hidradenitis suppurativa: haploinsufficiency of gamma-secretase components does not affect gamma-secretase enzyme activity <i>in vitro</i> . <i>British Journal of Dermatology</i> , 2016, 175, 632-635.	1.5	11
76	Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. <i>Nature Genetics</i> , 2016, 48, 510-518.	21.4	617
77	Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 593-602.	0.7	27
78	Update on psoriasis immunopathogenesis and targeted immunotherapy. <i>Seminars in Immunopathology</i> , 2016, 38, 11-27.	6.1	171
79	Demographics and disease characteristics of patients with psoriasis enrolled in the <sc>B</sc> ritish <sc>A</sc> ssociation of <sc>D</sc> ermatologists <sc>B</sc> iologic <sc>I</sc> nterventions <sc>R</sc> egister. <i>British Journal of Dermatology</i> , 2015, 173, 510-518.	1.5	87
80	Genome-wide Comparative Analysis of Atopic Dermatitis and Psoriasis Gives Insight into Opposing Genetic Mechanisms. <i>American Journal of Human Genetics</i> , 2015, 96, 104-120.	6.2	163
81	Psoriasis and Cardiometabolic Traits: Modest Association but Distinct Genetic Architectures. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1283-1293.	0.7	56
82	Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2964-2970.	0.7	89
83	The European Genome-phenome Archive of human data consented for biomedical research. <i>Nature Genetics</i> , 2015, 47, 692-695.	21.4	338
84	IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1067-1070.e9.	2.9	115
85	A global reference for human genetic variation. <i>Nature</i> , 2015, 526, 68-74.	27.8	13,998
86	Genetics of Psoriasis. <i>Dermatologic Clinics</i> , 2015, 33, 1-11.	1.7	76
87	Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions. <i>British Journal of Dermatology</i> , 2015, 172, 933-939.	1.5	17
88	Generalized Pustular Eruptions: Time to Adapt the Disease Taxonomy to the Genetic Architecture?. <i>Journal of Investigative Dermatology</i> , 2014, 134, 580-581.	0.7	5
89	Psoriasis heritability: 125 years and counting. <i>British Journal of Dermatology</i> , 2014, 171, 3-5.	1.5	8
90	Pentazocine-induced cutaneous scarring. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 115-116.	1.3	3

#	ARTICLE	IF	CITATIONS
91	Integrative Biology Approach Identifies Cytokine Targeting Strategies for Psoriasis. <i>Science Translational Medicine</i> , 2014, 6, 223ra22.	12.4	41
92	Loss of IL36RN Function Does Not Confer Susceptibility to Psoriasis Vulgaris. <i>Journal of Investigative Dermatology</i> , 2014, 134, 271-273.	0.7	25
93	Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2014, 170, 1237-1247.	1.5	39
94	Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study. <i>British Journal of Dermatology</i> , 2014, 171, 267-273.	1.5	52
95	Genome-wide association study identifies three novel susceptibility loci for severe Acne vulgaris. <i>Nature Communications</i> , 2014, 5, 4020.	12.8	68
96	Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. <i>British Journal of Dermatology</i> , 2014, 171, 17-29.	1.5	72
97	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 871-881.e30.	1.2	423
98	AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking. <i>American Journal of Human Genetics</i> , 2014, 94, 790-797.	6.2	153
99	Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. <i>British Journal of Dermatology</i> , 2013, 169, 306-313.	1.5	65
100	Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1366-1369.	0.7	140
101	Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. <i>Nature</i> , 2013, 498, 232-235.	27.8	184
102	Î³-Secretase Mutations in Hidradenitis Suppurativa: New Insights into Disease Pathogenesis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 601-607.	0.7	133
103	Psoriasis and Cardiovascular Disease: Where Is the Risk?. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2308-2311.	0.7	4
104	Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. <i>Journal of Dermatological Treatment</i> , 2013, 24, 38-49.	2.2	25
105	Rare Variations in IL36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1904-1907.	0.7	107
106	An In-Depth Characterization of the Major Psoriasis Susceptibility Locus Identifies Candidate Susceptibility Alleles within an HLA-C Enhancer Element. <i>PLoS ONE</i> , 2013, 8, e71690.	2.5	45
107	Psoriasis and Other Complex Trait Dermatoses: From Loci to Functional Pathways. <i>Journal of Investigative Dermatology</i> , 2012, 132, 915-922.	0.7	82
108	Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. <i>Human Molecular Genetics</i> , 2012, 21, 5185-5192.	2.9	58

#	ARTICLE	IF	CITATIONS
109	Erythema nodosum. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, C50-C52.	0.5	1
110	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics, 2012, 44, 1341-1348.	21.4	848
111	Mutations in the Î³-Secretase Genes NCSTN , PSENEN , and PSEN1 Underlie Rare Forms of Hidradenitis Suppurativa (Acne Inversa). Journal of Investigative Dermatology, 2012, 132, 2459-2461.	0.7	126
112	Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci. American Journal of Human Genetics, 2012, 90, 636-647.	6.2	290
113	Identification of Rare, Disease-Associated Variants in the Promoter Region of the RNF114 Psoriasis Susceptibility Gene. Journal of Investigative Dermatology, 2012, 132, 1297-1299.	0.7	8
114	Allele-Specific Cytokine Responses at the HLA-C Locus: Implications for Psoriasis. Journal of Investigative Dermatology, 2012, 132, 635-641.	0.7	23
115	Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. British Journal of Dermatology, 2012, 166, 189-195.	1.5	34
116	Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study. British Journal of Dermatology, 2012, 167, 165-173.	1.5	21
117	Infliximab for the treatment of psoriasis in the U.K.: 9â€¦yearsâ€™ experience of infusion reactions at a single centre. British Journal of Dermatology, 2012, 167, 411-416.	1.5	22
118	Improving clinical trial design in psoriasis: Perspectives from the global dermatology community. Journal of Dermatological Treatment, 2011, 22, 187-193.	2.2	4
119	A Strategic Approach to Setting the Research Agenda in Psoriasis. Psoriasis Forum, 2011, 17a, 97-102.	0.1	3
120	A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. British Journal of Dermatology, 2011, 164, 26-32.	1.5	32
121	Systemic antipsoriatic therapy may reverse endothelial dysfunction: reply from authors. British Journal of Dermatology, 2011, 164, 1398-1398.	1.5	0
122	Methotrexate or fumarates: which is the best oral treatment for psoriasis?. British Journal of Dermatology, 2011, 164, 695-695.	1.5	5
123	Psoriasis, cardiovascular disease and flowâ€¦mediated dilatation: reply from authors. British Journal of Dermatology, 2011, 165, 924-925.	1.5	0
124	Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 758-764.	2.4	74
125	Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis. American Journal of Human Genetics, 2011, 89, 432-437.	6.2	468
126	Meta-Analysis Confirms the LCE3C_LCE3B Deletion as a Risk Factor for Psoriasis in Several Ethnic Groups and Finds Interaction with HLA-Cw6. Journal of Investigative Dermatology, 2011, 131, 1105-1109.	0.7	89



#	ARTICLE	IF	CITATIONS
127	Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis. <i>Human Molecular Genetics</i> , 2011, 20, 3129-3137.	2.9	68
128	PSENER and NCSTN Mutations in Familial Hidradenitis Suppurativa (Acne Inversa). <i>Journal of Investigative Dermatology</i> , 2011, 131, 1568-1570.	0.7	103
129	The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 548-554.	2.4	135
130	Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. <i>British Journal of Dermatology</i> , 2010, 162, 427-434.	1.5	53
131	Antinuclear antibodies associate with loss of response to antitumour necrosis factor- $\alpha$ therapy in psoriasis: a retrospective, observational study. <i>British Journal of Dermatology</i> , 2010, 162, 780-785.	1.5	76
132	The development of sarcoidosis on antitumour necrosis factor therapy: a paradox. <i>British Journal of Dermatology</i> , 2010, 163, 648-649.	1.5	14
133	Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. <i>British Journal of Dermatology</i> , 2010, 163, 889-892.	1.5	21
134	A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2010, 163, 807-816.	1.5	54
135	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010, 42, 985-990.	21.4	918
136	Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1785-1796.	0.7	554
137	Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. <i>British Journal of Dermatology</i> , 2009, 160, 438-441.	1.5	64
138	Care of patients with psoriasis: an audit of U.K. services in secondary care. <i>British Journal of Dermatology</i> , 2009, 160, 557-564.	1.5	27
139	British Association of Dermatologists's™ guidelines for biologic interventions for psoriasis 2009. <i>British Journal of Dermatology</i> , 2009, 161, 987-1019.	1.5	412
140	Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. <i>Genes and Immunity</i> , 2009, 10, 654-658.	4.1	53
141	Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1394-1397.	2.4	27
142	Psoriasis. <i>New England Journal of Medicine</i> , 2009, 361, 496-509.	27.0	2,498
143	Prevalent and Low-Frequency Null Mutations in the Filaggrin Gene Are Associated with Early-Onset and Persistent Atopic Eczema. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1591-1594.	0.7	95
144	Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. <i>British Journal of Dermatology</i> , 2008, 158, 962-968.	1.5	41

#	ARTICLE	IF	CITATIONS
145	Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. <i>Current Medical Research and Opinion</i> , 2008, 24, 1237-1254.	1.9	46
146	Identification of ZNF313 / RNF114 as a novel psoriasis susceptibility gene. <i>Human Molecular Genetics</i> , 2008, 17, 1938-1945.	2.9	176
147	Recommendations for the Long-Term Treatment of Psoriasis with Infliximab: A Dermatology Expert Group Consensus. <i>Dermatology</i> , 2008, 217, 268-275.	2.1	33
148	Psoriasis as a systemic disease. <i>Expert Review of Dermatology</i> , 2008, 3, S25-S29.	0.3	0
149	The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. <i>Archives of Dermatological Research</i> , 2007, 298, 309-319.	1.9	110
150	Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. <i>Journal of Medical Genetics</i> , 2007, 45, 114-116.	3.2	139
151	Null Mutations in the Filaggrin Gene (FLG) Determine Major Susceptibility to Early-Onset Atopic Dermatitis that Persists into Adulthood. <i>Journal of Investigative Dermatology</i> , 2007, 127, 564-567.	0.7	298
152	Filaggrin Null Alleles Are Not Associated with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1878-1882.	0.7	41
153	A classification of psoriasis vulgaris according to phenotype. <i>British Journal of Dermatology</i> , 2007, 156, 258-262.	1.5	257
154	Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. <i>Human Genetics</i> , 2007, 122, 201-206.	3.8	373
155	Genetics of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 42-51.	2.4	14
156	Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. <i>British Journal of Dermatology</i> , 2006, 154, 345-352.	1.5	74
157	Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. <i>British Journal of Dermatology</i> , 2006, 155, 160-169.	1.5	49
158	Expression of the myelomonocytic antigens L1 and CD36 in human epidermis. <i>British Journal of Dermatology</i> , 2006, 123, 548-549.	1.5	4
159	Diffuse plane xanthomatosis and acquired palmoplantar keratoderma in association with myeloma. <i>British Journal of Dermatology</i> , 2006, 132, 286-289.	1.5	19
160	Does topical tacrolimus induce lentiginos in children with atopic dermatitis? A report of three cases. <i>British Journal of Dermatology</i> , 2005, 152, 152-154.	1.5	33
161	Functional MASP2 single nucleotide polymorphism plays no role in psoriasis. <i>British Journal of Dermatology</i> , 2005, 152, 1313-1315.	1.5	12
162	British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. <i>British Journal of Dermatology</i> , 2005, 153, 486-497.	1.5	245

#	ARTICLE	IF	CITATIONS
163	The Major Psoriasis Susceptibility Locus PSORS1 Is not a Risk Factor for Late-Onset Psoriasis. <i>Journal of Investigative Dermatology</i> , 2005, 124, 103-106.	0.7	85
164	Absence of Association Between Asthma and High Serum Immunoglobulin E Associated GPRA Haplotypes and Adult Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2005, 125, 399-401.	0.7	23
165	Genetic Association Analysis Using Data from Triads and Unrelated Subjects. <i>American Journal of Human Genetics</i> , 2005, 76, 592-608.	6.2	69
166	A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. <i>Human Molecular Genetics</i> , 2004, 13, 2361-2368.	2.9	240
167	Meta-Analysis of Genome-Wide Studies of Psoriasis Susceptibility Reveals Linkage to Chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans Population. <i>Journal of Investigative Dermatology</i> , 2004, 122, 1401-1405.	0.7	81
168	An update on the genetics of psoriasis. <i>Dermatologic Clinics</i> , 2004, 22, 339-347.	1.7	80
169	A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasis. <i>Experimental Dermatology</i> , 2003, 12, 506-509.	2.9	26
170	Genetic Analysis of PSORS1 Distinguishes Guttate Psoriasis and Palmoplantar Pustulosis. <i>Journal of Investigative Dermatology</i> , 2003, 120, 627-632.	0.7	190
171	EndoPDI, a Novel Protein-disulfide Isomerase-like Protein That Is Preferentially Expressed in Endothelial Cells Acts as a Stress Survival Factor. <i>Journal of Biological Chemistry</i> , 2003, 278, 47079-47088.	3.4	149
172	Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 µg/g ointment; no correlation with extent of psoriasis. <i>Journal of Dermatological Treatment</i> , 2003, 14, 14-21.	2.2	19
173	Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. <i>Human Molecular Genetics</i> , 2002, 11, 589-597.	2.9	131
174	Mediation of Systemic Vascular Hyperpermeability in Severe Psoriasis by Circulating Vascular Endothelial Growth Factor. <i>Archives of Dermatology</i> , 2002, 138, 791-6.	1.4	81
175	Family-Based Analysis Using a Dense Single-Nucleotide Polymorphism-Based Map Defines Genetic Variation at PSORS1, the Major Psoriasis-Susceptibility Locus. <i>American Journal of Human Genetics</i> , 2002, 71, 554-564.	6.2	130
176	Searching for the Major Histocompatibility Complex Psoriasis Susceptibility Gene. <i>Journal of Investigative Dermatology</i> , 2002, 118, 745-751.	0.7	140
177	Pharmacogenetics in clinical dermatology. <i>British Journal of Dermatology</i> , 2002, 146, 2-6.	1.5	23
178	Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. <i>British Journal of Dermatology</i> , 2002, 146, 824-831.	1.5	135
179	Immunohistochemical evaluation of psoriatic plaques following selective photothermolysis of the superficial capillaries. <i>British Journal of Dermatology</i> , 2001, 145, 45-53.	1.5	62
180	Contrasting patterns of streptococcal superantigen-induced T-cell proliferation in guttate vs. chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2001, 145, 245-251.	1.5	39

#	ARTICLE	IF	CITATIONS
181	Genetic aspects of psoriasis. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 321-325.	1.3	71
182	Pneumonitis complicating methotrexate therapy for pustular psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 247-249.	2.4	16
183	Corneodesmosin Expression in Psoriasis Vulgaris Differs from Normal Skin and Other Inflammatory Skin Disorders. <i>Laboratory Investigation</i> , 2001, 81, 969-976.	3.7	67
184	Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. <i>Journal of Medical Genetics</i> , 2001, 38, 7-13.	3.2	127
185	Foreword. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 457-457.	1.3	0
186	Editorial. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 458-458.	1.3	1
187	Characterization of the Major Susceptibility Region for Psoriasis at Chromosome 6p21.3. <i>Journal of Investigative Dermatology</i> , 1999, 113, 322-328.	0.7	91
188	Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. <i>British Journal of Dermatology</i> , 1999, 141, 274-278.	1.5	93
189	Genetics of psoriasis. <i>Journal of Dermatological Treatment</i> , 1998, 9, S3-S5.	2.2	0
190	Identification of a Major Susceptibility Locus on Chromosome 6p and Evidence for Further Disease Loci Revealed by a Two Stage Genome-Wide Search in Psoriasis. <i>Human Molecular Genetics</i> , 1997, 6, 813-820.	2.9	476
191	Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. <i>British Journal of Dermatology</i> , 1997, 136, 859-865.	1.5	29
192	Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. <i>British Journal of Dermatology</i> , 1997, 136, 859-865.	1.5	65
193	Ramipril-associated lichen planus pemphigoides. <i>British Journal of Dermatology</i> , 1997, 136, 412-414.	1.5	24
194	Circulating vascular permeability factor/vascular endothelial growth factor in erythroderma. <i>Lancet, The</i> , 1996, 348, 1101.	13.7	33
195	Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 137-145.	6.7	114
196	Vascular proliferation and angiogenic factors in psoriasis. <i>Clinical and Experimental Dermatology</i> , 1995, 20, 6-9.	1.3	38
197	An association between psoriasis and hereditary multiple exostoses. A clue for the mapping of a psoriasis susceptibility gene?. <i>British Journal of Dermatology</i> , 1994, 130, 671-674.	1.5	10
198	The immunopathology of psoriasis. <i>Bailliere's Clinical Rheumatology</i> , 1994, 8, 429-438.	1.0	24

#	ARTICLE	IF	CITATIONS
199	The tissue distribution of factor XIIIa positive cells. <i>Histopathology</i> , 1993, 22, 157-162.	2.9	57
200	A case of chromoblastomycosis responding to treatment with itraconazole. <i>British Journal of Dermatology</i> , 1993, 128, 436-439.	1.5	30
201	Excess melanocytic nevi in children with renal allografts. <i>Journal of the American Academy of Dermatology</i> , 1993, 28, 51-55.	1.2	98
202	Vascular cell adhesion molecule-1: Expression in normal and diseased skin and regulation in vivo by interferon gamma. <i>Journal of the American Academy of Dermatology</i> , 1993, 29, 67-72.	1.2	86
203	Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: In situ expression of I <sup>2</sup> -integrins. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 383-388.	1.2	29
204	Preferential adherence of T lymphocytes and neutrophils to psoriatic epidermis. <i>British Journal of Dermatology</i> , 1992, 127, 205-211.	1.5	27
205	Cutaneous lymphocyte trafficking in the inflammatory dermatoses. <i>British Journal of Dermatology</i> , 1992, 126, 211-215.	1.5	23
206	Clinicopathological features of Chromoblastomycosis—a case report. <i>British Journal of Dermatology</i> , 1992, 127, 82-83.	1.5	0
207	Keratinocytes as initiators of inflammation. <i>Lancet, The</i> , 1991, 337, 211-214.	13.7	724
208	Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNF- $\pm$ ) in allergic contact dermatitis (rhus dermatitis). <i>British Journal of Dermatology</i> , 1991, 124, 519-526.	1.5	158
209	(39) Atrophic papulosis associated with systemic lupus erythematosus. <i>British Journal of Dermatology</i> , 1991, 125, 66-67.	1.5	0
210	(57) Actinic granuloma annulare. <i>British Journal of Dermatology</i> , 1991, 125, 79a-80.	1.5	2
211	Antigenic profile of human acrosyringium. <i>British Journal of Dermatology</i> , 1991, 125, 413-418.	1.5	14
212	Pulmonary capillary leak syndrome complicating generalized pustular psoriasis: possible role of cytokines. <i>British Journal of Dermatology</i> , 1991, 125, 472-474.	1.5	31
213	The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin. <i>Clinical and Experimental Dermatology</i> , 1991, 16, 131-132.	1.3	44
214	Alterations induced in normal human skin by in vivo interferon-gamma. <i>British Journal of Dermatology</i> , 1990, 122, 451-458.	1.5	62
215	Distribution of intercellular-adhesion molecule-1 (ICAM-1) and lymphocyte-function-associated antigen-1 (LFA-1) in epidermal tumours. <i>Clinical and Experimental Dermatology</i> , 1990, 15, 331-334.	1.3	15
216	Keratinocyte expression of OKM5 antigen in inflammatory cutaneous disease. <i>British Journal of Dermatology</i> , 1989, 120, 613-618.	1.5	29

#	ARTICLE	IF	CITATIONS
217	Palmoplantar keratoderma, curly hair and endomyocardial fibrodysplasia: A new syndrome. British Journal of Dermatology, 1988, 119, 13-14.	1.5	22
218	(28) Dermatology at Guy's Hospital: the first hundred years. British Journal of Dermatology, 1988, 119, 58-59.	1.5	0
219	(40) Erythropoietic protoporphyria with hepatic involvement. British Journal of Dermatology, 1988, 119, 94-95.	1.5	0
220	(60) Basal cell naevus syndrome (lacking basal cell carcinomata). British Journal of Dermatology, 1988, 119, 113-114.	1.5	3
221	Hamartoma moniliformis - a case report. Clinical and Experimental Dermatology, 1988, 13, 34-35.	1.3	2
222	Eruptive dysplastic naevi following renal transplantation. Clinical and Experimental Dermatology, 1988, 13, 123-125.	1.3	57
223	Products of class II major histocompatibility complex gene subregions are differentially expressed on keratinocytes in cutaneous diseases. Journal of the American Academy of Dermatology, 1988, 19, 667-672.	1.2	8
224	Specific Binding of IGE by Cutaneous Antigen Presenting Cells in Atopic Dermatitis. Clinical Science, 1987, 73, 17P-17P.	0.0	0
225	Class II MHC Subregion Products Are Differentially Expressed by Keratinocytes in Cutaneous Diseases. Clinical Science, 1987, 73, 17P-18P.	0.0	0
226	(20) Radiological assessment of neurocutaneous disorders: application of new imaging techniques. British Journal of Dermatology, 1987, 117, 42-42.	1.5	0
227	Going through a rough patch: Oral adverse effects of secukinumab. Oral Surgery, 0, , .	0.2	0